SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Jacob Sands

Jacob Sands

Dana-Farber Cancer Institute, Boston

Dr. Jacob Sands is a thoracic medical oncologist and Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, where he also serves as an Assistant Professor at Harvard Medical School. He leads the institute’s clinical small cell lung cancer program and conducts trials of novel therapies, with a particular focus on antibody-drug conjugates such as datopotamab deruxtecan, alongside work to advance lung cancer screening and early detection. He sits on the NCCN guidelines committees for small cell lung cancer and CT lung screening and the IASLC Screening and Early Detection Committee, and is a frequent speaker at major international oncology congresses.

Connect

Jacob Sands

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates